^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MEK2 inhibitor

    Related drugs:
    4d
    A vasculogenic mimicry subtype unveiled by integrated multi-omics predicts prognosis and guides immunotherapy in MIBC. (PubMed, Front Bioinform)
    Combined treatment with the MEK inhibitor TAK-733 and immune checkpoint inhibitors was proposed as a promising therapeutic strategy for this subgroup. This novel VM-based molecular subtyping system for MIBC shows strong potential for clinical application in prognosis prediction, immunotherapy response evaluation, and targeted drug discovery, providing a framework to guide personalized treatment strategies for MIBC patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    REC-4881
    2ms
    MAPKeeper 301: Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P3, N=510, Recruiting, Immuneering Corporation
    New P3 trial
    |
    gemcitabine • albumin-bound paclitaxel • atebimetinib (IMM-1-104)
    2ms
    A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Focus V (anlotinib) • Fumaining (luvometinib)
    2ms
    TUPELO: Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) (clinicaltrials.gov)
    P1/2, N=67, Recruiting, Recursion Pharmaceuticals Inc. | Trial completion date: Jul 2026 --> Sep 2027 | Trial primary completion date: Jul 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    APC (APC Regulator Of WNT Signaling Pathway)
    |
    REC-4881
    2ms
    Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas (clinicaltrials.gov)
    P3, N=177, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    NF1 (Neurofibromin 1)
    |
    TQ-B3234
    4ms
    Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, West China Second University Hospital
    New trial
    |
    CD20 positive
    |
    vincristine • prednisone • Fumaining (luvometinib) • mercaptopurine
    4ms
    Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas (clinicaltrials.gov)
    P3, N=177, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial
    |
    NF1 (Neurofibromin 1)
    |
    TQ-B3234
    4ms
    A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation (clinicaltrials.gov)
    P2, N=18, Terminated, Recursion Pharmaceuticals Inc. | N=60 --> 18 | Trial completion date: Jan 2027 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Feb 2025; Study was terminated due to sponsor decision. This decision was not related to safety concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    APC (APC Regulator Of WNT Signaling Pathway) • RAS (Rat Sarcoma Virus) • AXIN1 (Axin 1)
    |
    REC-4881
    5ms
    Application Demonstration Program of Luvometinib for Pediatric and Adolescent Patients Aged 2 Years and Older with Symptomatic, Unresectable Plexiform Neurofibromas (PN) Associated with Neurofibromatosis Type 1 (NF1)(Demonstration project for the application of luvometinib in the treatment of neurofibromatosis type 1(rare disease)) (ChiCTR2500115360)
    P4, N=100, Not yet recruiting, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiao Tong University Sc
    New P4 trial
    |
    NF1 (Neurofibromin 1)
    |
    Fumaining (luvometinib)
    5ms
    Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions (clinicaltrials.gov)
    P=N/A, N=62, Recruiting, West China Second University Hospital
    New trial
    |
    Fumaining (luvometinib)
    8ms
    A single center, single arm, prospective clinical study initiated by a researcher on the efficacy and safety of FCN-159 table (ChiCTR2500109679)
    P=N/A, N=20, Completed, Beijing Childrens Hospital,Capital Medical University; Beijing Childrens Hospital,Capital Medical University
    New trial
    |
    Fumaining (luvometinib)
    8ms
    Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas. (PubMed, Target Oncol)
    Luvometinib had a manageable safety profile in pediatric patients with unresectable NF1-related PN. Encouraging preliminary efficacy was observed, particularly among patients receiving the RP2D of 5 mg/m2, supporting further investigation of luvometinib in this setting.
    P1 data • Journal
    |
    NF1 (Neurofibromin 1)
    |
    Fumaining (luvometinib)